Synta (SNTA) Suspends Trial Due To Higher Deaths
More News related to SNTA
- Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com
- Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090
- Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
- Synta Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
- Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) said based on an analysis by an independent Data Monitoring Committee, it has suspended the SYMMETRYSM trial, the Phase 3 clinical study comparing elesclomol in combination with paclitaxel to paclitaxel alone in chemo-naïve patients with stage IV metastatic melanoma.
The decision to suspend the SYMMETRY trial was based on the results of an analysis by the independent DMC which identified safety concerns, including an imbalance in overall survival (OS), with a greater number of deaths occurring in the combination arm (elesclomol with paclitaxel) compared to the control arm (paclitaxel alone). The final analysis of the primary endpoint (PFS) as assessed by independent reviewers has not been carried out yet.
Related Categories
FDAHot List
Stocks Mentioned
+0.00Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
snta
martin moriarty on Mar 2, 2009 05:10 PMI expect snta to be upgraded to buy very soon and stock to move to $5.00 by 3/30/09